Drug profile · INN
ibritumomab tiuxetan
ZEVALIN
ibritumomab tiuxetan (ZEVALIN) is a b-lymphocyte antigen cd20 binding agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — ibritumomab tiuxetan
- US status
- approved
- Class
- Various (V10)
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ibritumomab tiuxetan (ZEVALIN) is a b-lymphocyte antigen cd20 binding agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
B-lymphocyte antigen CD20 binding agent
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | unknown | — |
Related & competitor drugs
Frequently asked questions
What is ibritumomab tiuxetan?
ibritumomab tiuxetan (ZEVALIN) is a b-lymphocyte antigen cd20 binding agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ibritumomab tiuxetan?
ZEVALIN is a marketed brand name for ibritumomab tiuxetan. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ibritumomab tiuxetan?
ibritumomab tiuxetan has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.